Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model
Patrick Sieber, Anny Schäfer, Raphael Lieberherr, Silvia L. Caimi, Urs Lüthi, Jesper Ryge, Jan H. Bergmann, François Le Goff, Manuel Stritt, Peter Blattmann, Bérengère Renault, Patrick Rammelt, Bruno Sempere, Diego Freti, Rolf Studer, Eric S. White, Magdalena Birker-Robaczewska, Maxime Boucher, Oliver Nayler
Patrick Sieber, Anny Schäfer, Raphael Lieberherr, Silvia L. Caimi, Urs Lüthi, Jesper Ryge, Jan H. Bergmann, François Le Goff, Manuel Stritt, Peter Blattmann, Bérengère Renault, Patrick Rammelt, Bruno Sempere, Diego Freti, Rolf Studer, Eric S. White, Magdalena Birker-Robaczewska, Maxime Boucher, Oliver Nayler
View: Text | PDF
Research Article Cell biology Pulmonology

NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model

  • Text
  • PDF
Abstract

In the progression phase of idiopathic pulmonary fibrosis (IPF), the normal alveolar structure of the lung is lost and replaced by remodeled fibrotic tissue and by bronchiolized cystic airspaces. Although these are characteristic features of IPF, knowledge of specific interactions between these pathological processes is limited. Here, the interaction of lung epithelial and lung mesenchymal cells was investigated in a coculture model of human primary airway epithelial cells (EC) and lung fibroblasts (FB). Single-cell RNA sequencing revealed that the starting EC population was heterogenous and enriched for cells with a basal cell signature. Furthermore, fractions of the initial EC and FB populations adopted distinct pro-fibrotic cell differentiation states upon cocultivation, resembling specific cell populations that were previously identified in lungs of patients with IPF. Transcriptomic analysis revealed active NF-κB signaling early in the cocultured EC and FB, and the identified NF-κB expression signatures were found in “HAS1 High FB” and “PLIN2+ FB” populations from IPF patient lungs. Pharmacological blockade of NF-κB signaling attenuated specific phenotypic changes of EC and prevented FB-mediated interleukin-6, interleukin-8, and CXC chemokine ligand 6 cytokine secretion, as well as collagen α-1(I) chain and α–smooth muscle actin accumulation. Thus, we identified NF-κB as a potential mediator, linking epithelial pathobiology with fibrogenesis.

Authors

Patrick Sieber, Anny Schäfer, Raphael Lieberherr, Silvia L. Caimi, Urs Lüthi, Jesper Ryge, Jan H. Bergmann, François Le Goff, Manuel Stritt, Peter Blattmann, Bérengère Renault, Patrick Rammelt, Bruno Sempere, Diego Freti, Rolf Studer, Eric S. White, Magdalena Birker-Robaczewska, Maxime Boucher, Oliver Nayler

×

Figure 5

Pharmacological intervention attenuates α-SMA and COL1 accumulation in cocultures of NHBE and NHLF.

Options: View larger image (or click on image) Download as PowerPoint
Pharmacological intervention attenuates α-SMA and COL1 accumulation in c...
NHLF and NHBE were seeded in full medium in the presence of (A) nintedanib, (B) pirfenidone, (C) EW-7197, (D) LLL12, (E) stattic, (F and H) BAY 11-7082, and (G and I) T-5224, at the indicated concentration range (0.025–25,000 nM), except for pirfenidone (0.01–10,000 μM). At t = 18 hours after seeding, cells were switched to starvation medium containing compounds at the indicated concentration (A–G) or solvent (H and I) for the remaining duration of the experiment. Lysis was performed 98 hours after seeding, and α-SMA and COL1 were quantified by MS/MS. The mean value of the normalized analyte level of the solvent control is given as 100%. Bars represent protein data normalized to tubulin (expressed as %) in relation to the solvent control and show mean ± SD; n = 8 (A and D–G), n = 11 (B), n = 26 (C), and n = 3 (H and I). Data for which cytotoxic effects are not excluded are omitted. A 2-way ANOVA with Tukey’s multiple-comparison test was used. P values of comparison to solvent control are depicted. **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. In all wells, 0.25% DMSO was present.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts